StockData
CONMED Corp logo

CONMED Corp (CNMD) stock

CNMDNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 14/3029% below fair value
$48.39−0.96 (-1.95%)

Close on Nov 17, 2026Market cap $1.44BP/E 20.0Yield 1.24%

Earnings

Conmed's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Jan 27, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$335.60M
-0.7% on a year earlier
Adjusted diluted earnings per share, Q3 FY2026
$1.04
$1.08 a year earlier
Latest guidance
Issued
Oct 28, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Conmed's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Jan 27, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 28, 2026after the close$335.60M-0.7%$0.66$1.04Release
Q2 FY2026ended Jun 30, 2026Jul 29, 2026during market hours$343.50M+0.4%$0.77$1.38Release
Q1 FY2026ended Mar 31, 2026Apr 29, 2026during market hours$317.00M-1.3%$0.45$0.89Release
Q4 FY2025ended Dec 31, 2025Jan 28, 2026during market hours$373.20M+7.9%$0.54$1.43Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025during market hours$337.90M+6.7%$0.09$1.08Release
Q2 FY2025ended Jun 30, 2025Jul 30, 2025during market hours$342.30M+3.1%$0.69$1.15Release
Q1 FY2025ended Mar 31, 2025Apr 30, 2025during market hours$321.30M+2.9%$0.19$0.95Release
Q4 FY2024ended Dec 31, 2024Feb 5, 2025during market hours$345.90M+5.8%$1.08$1.34Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024during market hours$316.70M+4.0%$1.57$1.05Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024during market hours$332.10M+4.5%$0.96$0.98Release
Q1 FY2024ended Mar 31, 2024Apr 24, 2024during market hours$312.30M+5.7%$0.63$0.79Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Conmed's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Net Sales (GAAP)GAAPFY2026$1.36B – $1.37B–NewOct 28, 2026
Net Sales (GAAP)GAAPFY2026$1.36B – $1.37B$1.35B – $1.38BNarrowedJul 29, 2026
Net Sales Growth, as reportedGAAPFY2026-1.2% – -0.1%–NewJul 29, 2026
Net Sales Growth, Constant Currencynon-GAAPFY2026-1.7% – -0.7%+5% – +6.5%LoweredJul 29, 2026
revenue from gastroenterology productsFY2026$14.50M – $17.50M–NewApr 29, 2026
Adjusted Diluted EPSnon-GAAPFY2026$4.54 – $4.61–NewOct 28, 2026
Adjusted Diluted EPSnon-GAAPFY2026$4.48 – $4.60$4.30 – $4.45RaisedJul 29, 2026
Percentage Changenon-GAAPFY2026-2.4% – +0.2%–NewJul 29, 2026

Guidance vs results

The last range Conmed gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025adjusted diluted net earnings per share$4.48 – $4.53$4.61Σ4QAbove range
FY2025Revenue$1.37B – $1.37B$1.37BΣ4QAbove range
Q3 FY2024Revenue$315.00M – $318.00M$316.70MWithin range

Guidance history

Every forecast Conmed put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 28, 2026Adjusted Diluted EPSFY2026$4.54 – $4.61New
Oct 28, 2026Net Sales (GAAP)FY2026$1.36B – $1.37BNew
Jul 29, 2026Percentage ChangeFY2026-2.4% – +0.2%New
Jul 29, 2026Adjusted Diluted EPSFY2026$4.48 – $4.60Raised
Jul 29, 2026Net Sales Growth, Constant CurrencyFY2026-1.7% – -0.7%Lowered
Jul 29, 2026Net Sales Growth, as reportedFY2026-1.2% – -0.1%New
Jul 29, 2026Net Sales (GAAP)FY2026$1.36B – $1.37BNarrowed
Jul 29, 2026Net Sales Growth, Organic Constant CurrencyFY2026+5% – +6%Raised
Apr 29, 2026adjusted diluted net earnings per shareFY2026$4.30 – $4.45Reaffirmed
Apr 29, 2026revenue from gastroenterology productsFY2026$14.50M – $17.50MNew
Apr 29, 2026organic constant currency revenue growthFY2026+5% – +6.5%Raised
Apr 29, 2026reported revenueFY2026$1.35B – $1.38BRaised
Jan 28, 2026adjusted diluted net earnings per shareFY2026$4.30 – $4.45New
Jan 28, 2026reported revenueFY2026$1.35B – $1.38BNew
Jan 28, 2026organic constant currency growthFY2026+4.5% – +6%New
Nov 5, 2025adjusted diluted net earnings per shareFY2025$4.48 – $4.53New
Nov 5, 2025reported revenueFY2025$1.37B – $1.37BNew
Jul 30, 2025adjusted diluted net earnings per shareFY2025$4.40 – $4.55Lowered
Jul 30, 2025reported revenueFY2025$1.36B – $1.38BRaised
Apr 30, 2025full-year adjusted diluted net earnings per shareFY2025$4.45 – $4.60Raised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Conmed filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Results
  5. Results
  6. Update
  7. Update
  8. Results
  9. Results
  10. Update
  11. Results
  12. News
  13. Results
  14. Update
  15. Results

See a number that looks wrong?